Cyprinol, 250 mg 10 pcs

Cyprinol refers to antibacterials for systemic use. Fluoroquinolones.

Ciprofloxacin inhibits the enzyme DNA-gyrase, inhibiting the ability of bacteria to reproduce. The drug has a bactericidal effect on microorganisms both during the reproduction phase and in the quiescent phase. Ciprinol is highly effective against almost all gram-negative and gram-positive pathogens. Salmonella spp, Shigella spp, Klebsiella spp, Escherichia coli, Citrobacter spp, Enterobacter spp, Hafnia spp, Serratia spp., Edwardsiella spp., Proteus, Providencia spp., Morganella spp., Aeromonasspp., Yersinia, Vibriospp., Haemophilus, Plesiomonas, Campylobacterspp., Pasteurella, Pseudomonasspp. (Including Pseudomonas aeruginosa), Neisseria spp., Legionella, Moraxella spp., Acinetobacter spp., Branhamella spp., Brucella spp., Listeria spp., Staphylococcus spp., Corynebacterium, Chlamydia, and plasmid forms of bacteria.

Different sensitivities show: Gardnerella spp., Streptococcus agalactiae, Alcaligenes spp., Flavobacterium spp., Streptococcus pyogenes, Streptococcus faecalis, Streptococcus pneumoniae, Mycoplasma hominis, Streptococcus viridans, Mycobacterium fortuitum, Mycobacterium tuberculosis. Anaerobic cocci (Pertococcus, Peptostreptococcus) are moderately sensitive to ciprofloxacin, and Bacteroides is resistant.

Ciprofloxacin is effective against beta-lactamase-producing bacteria. Ciprinol is active against microorganisms resistant to most antibiotics, sulfonamides and nitrofurans. Ciprofloxacin may be active against strains of microorganisms resistant to other drugs of fluoroquinolones group. However, it should be taken into account that there is cross-resistance between different fluoroquinolones. As a rule, Nocardia asteroides, Treponema pallidum, Streptococcus faecium, Ureaplasma urealyticum are resistant to Ciprinol. Resistance to ciprofloxacin develops slowly and gradually.

Indications

urinary tract infections,
gonorrhea,
pneumonia,
infections of the skin and soft tissues,
infections of bones and joints,
intestinal infections,
barley,
blood poisoning.

Pharmacological effect

Tsiprinol is an antibacterial agent for systemic use. Fluoroquinolones.

Ciprofloxacin inhibits the enzyme DNA gyrase, inhibiting the bacteria’s ability to reproduce. The drug has a bactericidal effect on microorganisms both during the reproduction period and in the resting phase. Tsiprinol is highly effective against almost all gram-negative and gram-positive pathogens. The following are sensitive to ciprofloxacin: Salmonella spp., Shigella spp., Klebsiella spp., Escherichia coli, Citrobacter spp., Enterobacter spp., Hafnia spp., Serratia spp., Edwardsiella spp., Proteus, Providencia spp., Morganella spp., Aeromonasspp., Yersinia, Vibriospp., Haemophilus, Plesiomonas, Campylobacterspp., Pasteurella, Pseudomonaspp. (Including Pseudomonas aeruginosa), Neisseria spp., Legionella, Moraxella spp., Acinetobacter spp., Branhamella spp., Brucella spp., Listeria spp., Staphylococcus spp., Corynebacterium, Chlamydia, and plasmid forms of bacteria.

Different sensitivity is shown by: Gardnerella spp., Streptococcus agalactiae, Alcaligenes spp., Flavobacterium spp., Streptococcus pyogenes, Streptococcus faecalis, Streptococcus pneumoniae, Mycoplasma hominis, Streptococcus viridans, Mycobacterium fortuitum, Mycobacterium tuberculosis. Anaerobic cocci (Peptococcus, Peptostreptococcus) are moderately sensitive to ciprofloxacin, and Bacteroides is resistant.

Ciprofloxacin is effective against bacteria that produce beta-lactamases. Tsiprinol is active against microorganisms resistant to most antibiotics, sulfonamide and nitrofuran drugs. Ciprofloxacin may be active against strains of microorganisms resistant to other drugs of the fluoroquinolone group. However, it must be taken into account that there is cross-resistance between different fluoroquinolones. As a rule, Nocardia asteroides, Treponema pallidum, Streptococcus faecium, Ureaplasma urealyticum are resistant to Tsiprinol. Resistance to ciprofloxacin develops slowly and gradually.

Special instructions

It should not be prescribed simultaneously with antacid drugs; the interval between the use of these drugs should be at least 2 hours. During the treatment period, it is necessary to receive a sufficient amount of fluid and it is not recommended to sunbathe.

If pain in the joints and ligaments occurs, treatment with Tsiprinol should be discontinued. Do not take simultaneously with antiarrhythmic drugs of classes I and III, tricyclic antidepressants.

Active ingredient

Ciprofloxacin

Composition

1 tablet contains:

CORE:

Active substance:

ciprofloxacin in the form of ciprofloxacin hydrochloride monohydrate 291 mg (which corresponds to ciprofloxacin – 250 mg).

Excipients:

microcrystalline cellulose,

sodium carboxymethyl starch (type A),

povidone,

croscarmellose sodium,

silicon dioxide colloidal anhydrous,

magnesium stearate.

SHELL:

hypromellose, talc, titanium dioxide, E171, propylene glycol.

Contraindications

hypersensitivity to the drug Tsiprinol,
severe renal dysfunction,
epilepsy.

Side Effects

allergic reactions
swelling of the face, vocal cords
abdominal pain, nausea, vomiting, diarrhea
sleep disturbances, headache, anxiety, general depression
changes in the blood picture; disturbance in the perception of smell and taste.

Interaction

When ciprofloxacin is combined with antacids (containing aluminum, magnesium or calcium) or sucralfate, the absorption of ciprofloxacin is reduced. Therefore, it is recommended to take ciprofloxacin either 4 hours before using antacids or sucralfate, or 2-4 hours after taking it.

Medicines containing iron or zinc reduce the absorption of ciprofloxacin. Concomitant use of ciprofloxacin and theophylline and/or caffeine may cause an increase in serum theophylline and/or caffeine levels and increase their elimination time. The risk of these side effects increases. The simultaneous administration of cyclosporine and ciprofloxacin increases the nephrotoxicity of cyclosporine. Monitoring of serum theophylline and cyclosporine concentrations is necessary. Combining ciprofloxacin with oral anticoagulants may increase bleeding time, so prothrombin time should be monitored.

During treatment with ciprofloxacin there is a high risk of tendon rupture in patients who are simultaneously undergoing corticosteroid therapy. Combining ciprofloxacin with phenytoin may result in changes in phenytoin serum concentrations. Prescribe Tsiprinol with extreme caution when treating patients with diabetes mellitus, because the effect of glibenclamide may be enhanced and cause hypoglycemia. Concomitant use of NSAIDs (especially opioid analgesics) and very high doses of quinolones may cause convulsions.

Overdose

Symptoms include nausea, vomiting, diarrhea, headache and dizziness, and in more severe cases, confusion, tremors, hallucinations and seizures.

Treatment: symptomatic, gastric lavage, administration of activated charcoal and laxatives; ensure sufficient fluid supply. A specific antidote is unknown. Hemodialysis has no clinical effect in case of intoxication.

Storage conditions

Store in a dry place, protected from light, at a temperature not exceeding 25 °C. Keep out of the reach of children.

Shelf life

5 years.

Manufacturer

KRKA dd Novo Mesto, Slovenia